Interview With Joël Brierre

BIG news for Mydecine (MYCO : NEO) (MYCOF: OTC) and Numinus Wellness (NUMI: NEO)
(LKYSF : OTC). But The BIGGER NEWS is that we are finally launching our website: https://thepsychedelicinvestor.com/, where we will be sharing the latest industry news for all of your favorite companies.
We hope we can facilitate our community’s path to information about the psychedelic sector. We would like to invite you to share your opinions and suggestions down in the comment section.

Last but not least, if you wish to collaborate and become a contributor for The Psychedelic Investor, you’re welcome to send us an email at thepsychedelicinvestor@gmail.com or fill in a form on our website! We welcome your opinion and you can have a shot at seeing your name in the opinion section of our website!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Links:

Numinus Wellness (TSXV: NUMI, OTC: LKYSF), Filed a Patent Application for their Proprietary Rapid Production Process of Psilocybe Mushrooms and Other Psychoactive Fungi Species:
https://thepsychedelicinvestor.com/2021/06/24/numinus-files-u-s-provisional-patent-application-for-a-proprietary-rapid-production-process-for-psilocybe-and-other-psychoactive-fungi-species/

Mydecine (NEO: MYCO, OTC: MYCOF), Will Attempt To Treat Substance Use Disorder and Nicotine Addiction With Their MYCO-004 Molecule:
https://thepsychedelicinvestor.com/2021/06/24/mydecine-selects-substance-use-disorder-and-smoking-cessation-for-novel-psychedelic-molecule-myco-004/

Mydecine’s 4 Proprietary Compounds Advancing To Clinical Trials: Myco 001, 002, 003, 004:
https://thepsychedelicinvestor.com/2021/04/07/mydecine-announces-four-lead-novel-drug-candidates-and-prepares-for-pre-ind-meetings-with-the-fda-and-health-canada-to-prepare-for-human-clinical/

Johns Hopkins psilocybin study results:
https://www.hopkinsmedicine.org/news/stories/mushrooms_quit_smoking.html

Roth Capital Initiates Coverage On Mydecine Innovations with Buy Rating, Announces Price Target of 3$:
https://www.benzinga.com/news/21/06/21664391/roth-capital-initiates-coverage-on-mydecine-innovations-with-buy-rating-announces-price-target-of-c

Enjoy the episode!

Timestamps:
0:00 – Intro
1:37- Numinus’ patent application to speed up their psilobe mushrooms’ production process
4:53 – Mydecine announces it will use their MYCO – 004 molecule to treat substance use disorder and addiction
9:15 – Roth Capital says that Mydecine is a BUY with a price target of $3

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Numinus #Mydecine #NUMIStock

In our previous video, we discussed the upcoming IPO of Horizons Psychedelic ETF (PSYK).
Recently, on January 27th, PSYK began trading on the Canadian NEO Stock Exchange.
In this episode we are going to discuss the psychedelic ETF and what it means for MindMed, NUMI, Compass Pathways and other stocks in the psychedelic sector.

We will cover a few things such as:

– PSYK’s fundamentals
– PSYK’s CEO Steve Hawkins
-Is Horizons ETF actively or passively managed?
– What psychedelic stocks are included in the ETF?
– How often does th ETF reorganize its stock holdings?
– How is the size of the individual stocks’ position decided on?
– Is it worth investing in PSYK now?
– What will happen to MindMed (MMED/MMEDF), Numinus Wellness (NUMI), Compass Pathways (CMPS) and the other stocks once they are included?

***A quick reminder, the psychedelic sector is at a VERY early stage, and all of these companies, large-cap and small cap alike, will need to attract more funding to complete their clinical trials and bring their products to market. PSYK will however contribute to this sector as it will bring more funding to the industry as a whole, which will both help individual companies and the wider mission of treating mental health disorders.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#PSYK #MindMed #MMED

Donate to MAPS: https://maps.org/about-maps/our-team/

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

In today’s episode of Psychedelic Spotlight Podcast, James Hallifax from The Psychedelic Investor, had the pleasure of interviewing Rick Doblin, founder of MAPS. When it comes to psychedelic research, the questions of whether psychedelics can help with mental health, and the de-stigmatization of psychedelics, Rick Doblin is the certified G.O.A.T.

Can MDMA treat PTSD? Rick Doblin (and the science) says YES!

Should psychedelics be legalized? Rick Doblin (and facts and logic) say YES!

Did MDMA save the world from World War III? Rick Doblin says… okay well probably not. But it may have played a role!

To learn more about MAPS and their clinical trial, visit maps.org
While you are there, if you are feeling generous and want to donate to a good cause, MAPS is a charity.

Links:
MDMA and the Soviets
https://thebulletin.org/2021/12/psychedelics-the-newest-tool-in-nuclear-negotiations/

CBS MDMA for Veterans Interview
https://www.cbsnews.com/news/mdma-ecstasy-psychedelics-treating-veterans-ptsd/

Today Show MDMA for Veterans Interview
https://www.today.com/health/mdma-ptsd-study-veteran-shares-experience-rcna4495

#RickDoblin #MDMA #PSYCHEDELICS